Two Chinese provinces report 5 more H7N9 cases
Routine disease surveillance reports for November from two of China's provinces reveal five more H7N9 avian flu cases, according to official reports translated and posted by FluTrackers, an infectious disease news message board.
Four of the infections are in Jiangsu province, while the other is from Fujian province. No other details were reported about the patients. In its fifth wave of H7N9 activity, China now has reported eight cases, including an earlier one from Jiangsu province.
The new illnesses lift the global number of H7N9 cases since the novel virus was first detected in humans in 2013 to 815, according to a case list maintained by FluTrackers.
Dec 12 FluTrackers thread on Jiangsu provinces cases
Dec 12 FluTrackers thread on Fujian province case
FluTrackers global H7N9 case list
France reports low-path H5N1 avian flu
Today the World Organization for Animal Health (OIE) said France is reporting its first outbreak of low-pathogenic H5N1 avian influenza in 1,000 ducks on a farm in the southern part of that country.
H5N1 was detected after the birds were sampled as part of routine surveillance for H5N8 because of activity of highly pathogenic avian flu in the region. The farm is located in Pallanne, near Monlezun, which has reported several outbreaks of H5N8 in recent weeks.
In other avian flu news, the OIE said Finland has reported several detections of H5N8 in wild ducks and eagles. The birds were found dead on the southern islands of the country.
Finally today, Avian Flu Diary, an infectious disease blog, said Japan's environmental ministry is reporting 22 new reports of H5N6 in wild birds.
Dec 12 OIE France report
First generic oseltamivir hits US market
A generic version of the flu antiviral drug oseltamivir (Tamiflu) hit the US market today, drug company Alvogen, Inc, of Pine Brook, N.J., said in a news release.
The company launched the equivalent of Tamiflu capsules, available in 30-, 45-, and 75-milligram doses, in partnership with Natco Pharma of India. The new drug could save up to $500 million in the upcoming flu season, Alvogen said.
Sales of Tamiflu in 2015 reached about $400 million, The Economic Times of India reported. Tamiflu sales peaked during the 2009 H1N1 pandemic, with revenues approaching $3 billion, according to Reuters.
Alvogen has 79 products in development and pending Food and Drug Administration approval for the US market, the company said.
Dec 12 Alvogen news release
Dec 12 Economic Times story
Dec 12 Reuters report